Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D GLAZER

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
American Heart Journal|January 6, 2005
Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT)Lawrence Baruch, Robert D Glazer, Nora Aknay, et al.
The Journal of Invasive Cardiology|November 3, 2012
Learning curve in transradial cardiac catheterization: procedure-related parameters stratified by operators' transradial volumeEhab S Kasasbeh, Babar Parvez, Robert L Huang, et al.
Circulation|March 12, 2003
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT)Inder S Anand, Lloyd D Fisher, Yann-Tong Chiang, et al.
Pediatric Nephrology (Berlin, Germany)|November 7, 2018
Long-term safety and tolerability of valsartan in children aged 6 to 17 years with hypertensionRandall Lou-Meda, Brigitte Stiller, Zenaida L Antonio, et al.
Journal of the American Academy of Dermatology|May 11, 1991
A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neckE A Olsen, M L Abernethy, C Kulp-Shorten, et al.
Circulation|August 17, 2005
Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFTInder S Anand, Michael A Kuskowski, Thomas S Rector, et al.
Archives of Dermatology|January 21, 2004
Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trialsDaniel J Piacquadio, Diana M Chen, Harold F Farber, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
American Heart Journal|January 6, 2005
Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT)Lawrence Baruch, Robert D Glazer, Nora Aknay, et al.
The Journal of Invasive Cardiology|November 3, 2012
Learning curve in transradial cardiac catheterization: procedure-related parameters stratified by operators' transradial volumeEhab S Kasasbeh, Babar Parvez, Robert L Huang, et al.
Circulation|March 12, 2003
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT)Inder S Anand, Lloyd D Fisher, Yann-Tong Chiang, et al.
Pediatric Nephrology (Berlin, Germany)|November 7, 2018
Long-term safety and tolerability of valsartan in children aged 6 to 17 years with hypertensionRandall Lou-Meda, Brigitte Stiller, Zenaida L Antonio, et al.
Journal of the American Academy of Dermatology|May 11, 1991
A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neckE A Olsen, M L Abernethy, C Kulp-Shorten, et al.
Circulation|August 17, 2005
Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFTInder S Anand, Michael A Kuskowski, Thomas S Rector, et al.
Archives of Dermatology|January 21, 2004
Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trialsDaniel J Piacquadio, Diana M Chen, Harold F Farber, et al.
Pageof 4